Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that it has retained Isserman Consulting to lead a comprehensive press communications and shareholder relations campaign. Based in Saint Louis, Isserman Consulting provides a variety of custom services for public companies seeking results-oriented investor relations programs.
"Nutra Pharma has a novel business strategy with a great story," commented Rik J Deitsch, President and CEO of Nutra Pharma. "We see gaining appropriate recognition for the Nutra Pharma story as an important priority. This is why we needed to partner with an investor relations firm that could help expand public awareness and get our story out to the investment community. We are encouraged in this effort by Isserman Consulting's knowledge base, ideas and perspective," he added.
"We are privileged to represent Nutra Pharma," said David Isserman, President and Founder of Isserman Consulting. "We have formed a great relationship with the management team and understand their long-term business plans and growth strategies. We agree with our client that they operate in an exciting industry and that as a small corporation they must be prepared to seek out and turn opportunities to their advantage quickly. We are prepared to help the Company communicate its story to the investment community and thus help Nutra Pharma achieve greater shareholder value," he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Engaging Isserman Consulting for public awareness and investor relations should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.